Structure Therapeutics announced its daily obesity pill resulted in a 16% weight loss relative to placebo after 44 weeks, positioning it as a potential competitor to Eli Lilly and Novo Nordisk's GLP-1 injection alternatives. GSK’s RSV vaccine received expanded U.S. approval for high-risk adults, broadening the eligible population by around 21 million and reassuring drugmakers amid increased scrutiny of immunizations. Content creators should highlight these medical advancements as significant developments in obesity treatment and respiratory virus protection.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
2
Comments
Ali NematiWritten by Ali
